Molecular characterization of polish blueberry red ringspot virus isolate

In this study, we determined the complete sequence of the genomic DNA of a Polish isolate of Blueberry red ringspot virus (BRRSV24) and compared it with a Czech (Darrow 5), and the US isolates of the virus and those of other Caulimoviridae family. The genomic DNA of BRRSV24 consists of 8,265 nucleotides and encodes eight open reading frames (ORFs). The sequence homologies of the eight ORFs of BRRSV24 were from 95 to 98% in respect of Darrow 5 and from 91 to 98% in respect of the US isolates at the amino acid level. This high level of amino acid sequence identity within the coding regions among the Czech, the US and Polish BRRSV isolates is suggestive of their common origin

Comparação da variação de resposta ao broncodilatador através da espirometria em portadores de asma ou doença pulmonar obstrutiva crônica Comparison of spirometric changes in the response to bronchodilators of patients with asthma or chronic obstructive pulmonary disease

OBJETIVO: O diagnóstico diferencial entre asma e doença pulmonar obstrutiva crônica (DPOC) através da resposta aos broncodilatadores inalatórios na espirometria ainda é controverso. O objetivo deste estudo foi detectar quais variáveis espirométricas melhor diferenciam asma de DPOC. MÉTODOS: Estudo retrospectivo realizado entre abril de 2004 e janeiro de 2006, comparando-se os parâmetros espirométricos de 103 pacientes asmáticos, não fumantes, com os de 108 pacientes portadores de DPOC, fumantes de mais de 10 anos-maço. Todos os pacientes tinham mais de 40 anos e apresentavam doença estável no momento do exame. RESULTADOS: O volume expiratório forçado no primeiro segundo (VEF1) pré-broncodilatador foi igual nos dois grupos (VEF1 = 51%), mas os portadores de DPOC eram mais velhos (66 ± 9 anos vs. 59 ± 11 anos, p < 0,001) e, na sua maioria, do sexo masculino (73% vs. 27%, p < 0,001). A mediana da variação absoluta do VEF1 pós-broncodilatador foi de 0,25 L (intervalo, -0,09 a 1,13 L) nos pacientes com asma e de 0,09 L (intervalo, -0,1 a 0,73 L) nos com DPOC (p < 0,001). A melhor combinação de sensibilidade (55%), especificidade (91%) e razão de verossimilhança (6,1) para o diagnóstico de asma foi obtida quando a percentagem de incremento do VEF1 pós-broncodilatador em relação ao VEF1 previsto foi igual ou maior que 10% (p < 0,001). Variações significativas isoladas da capacidade vital forçada foram mais comuns nos pacientes com DPOC. CONCLUSÕES: Em portadores de doenças pulmonares obstrutivas com mais de 40 anos, a &#916;%prevVEF1 > 10% constitui o melhor parâmetro espirométrico para diferenciar asma de DPOC.<br>OBJECTIVE: Making the differential diagnosis between asthma and chronic obstructive pulmonary disease (COPD) based on the response to inhaled bronchodilators by means of spirometry is controversial. The objective of this study was to identify the most useful spirometric variables in order to distinguish between asthma and COPD. METHODS: Retrospective study conducted from April of 2004 to January of 2006, comparing the spirometric parameters of 103 nonsmoking patients with asthma to those of 108 patients with COPD who were smokers for more than 10 pack-years. All of the patients included in the study were older than 40 and presented stable disease at the time of the test. RESULTS:Initial forced expiratory volume in one second (FEV1) was the same in the two groups (pre-bronchodilator VEF1 = 51%). However, patients with COPD were older (66 ± 9 years vs. 59 ± 11 years, p < 0.001) and more frequently male (73 vs. 27%, p < 0,001).After the use of the bronchodilator, the median absolute difference in FEV1 was 0.25 L (range, -0.09 to 1.13 L) in patients with asthma and 0.09 L (range, -0.1 to 0.73 L) in those with COPD (p < 0.001). The highest sensitivity (55%), specificity (91%) and likelihood ratio (6.1) for asthma diagnosis was obtained when the percentage increase in postbronchodilator FEV1 in relation to the predicted FEV1 (&#916;%prevVEF1) was equal to or greater than 10%. Isolated significant increases in forced vital capacity were more common in patients with COPD. CONCLUSIONS: In patients over the age of 40 and presenting obstructive lung disease, a &#916;%prevVEF1 > 10% is the best spirometric parameter to distinguish asthma from COPD

Efficacy of fungicides on mycelial growth of diatrypaceous fungi associated with grapevine trunk disease

Several species of Diatrypaceae have been recently isolated from the wood of cankered grapevines in several regions of the world and shown to be pathogenic with varying degrees of virulence when inoculated in stems of potted vines. Existing management strategies have focussed on the evelopment of procedures and products to prevent or reduce Eutypa lata infection. The best method to prevent infection is by applying fungicides to wounds, but there are few registered chemicals for any of the diatrypaceous fungi in Australia. Six selected fungicides were evaluated in vitro for their efficacy in reducing mycelial growth of Eutypa lata, Cryptovalsa ampelina, Diatrypella vulgaris, Eutypa leptoplaca, Eutypella citricola and Eutypella microtheca. Carbendazim, fluazinam, tebuconazole, and prothioconazole + tebuconazole were effective at inhibiting mycelial growth of all Diatrypaceae spp. tested. Pyraclostrobin reduced colony diameter of most of the fungal species by 50% or more. Pyrimethanil was ineffective at reducing mycelial growth of these pathogens. Five of the six fungicides evaluated in this study have shown efficacy in vitro against Diatrypaceae spp. and require further evaluation in the field. This study represents the first approach for fungicide evaluation against mycelial growth of diatrypaceous fungi, other than Ea. lata. It contributes to the development of integrated management strategies for grapevine trunk diseases. © 2011 Australasian Plant Pathology Society Inc.Peer Reviewe